Product Code: 978-1-68038-333-1
Hyaluronic Acid Market Growth & Trends:
The global hyaluronic acid market size is expected to reach USD 16.75 billion by 2030, registering a CAGR of 7.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Factors, such as increasing concern of population regarding chemicals, desire to get quick and evident results, and shorter recovery time are high impact rendering drivers. The industry is evolving rapidly due to the increasing adoption of aesthetic procedures in developed and developing regions. Increasing the use of hyaluronic acid surfaces in cardiovascular implants, such as stents and vascular grafts, for improving compatibility coupled with the growing awareness about anti-aging products is fueling the growth.
The efficacy and evident results of hyaluronic acid-based dermal fillers are attracting this population base. Furthermore, the COVID-19 pandemic has changed the dynamics of many industries, with movement restrictions, social distancing, and revised practices becoming the "new normal." As the cosmetic industry is gradually resuming its operations, a number of doctors have reported a significant increase in inquiries for aesthetic surgeries. Moreover, the lockdown has encouraged all professionals to use video-conferencing facilities, which has made people more conscious of their looks. In some cases, it has led people to opt for cosmetic treatments; this is termed the "Zoom Boom" or the "Zoom effect."
Cosmetic surgeons across the world have witnessed a significant increase in the number of patients as a result of the pandemic, particularly in countries, such as the U.S., Australia, and Japan. North America held the maximum revenue share in 2022. Preference for short-treatment regimens, even though high-priced, and the prevalence of target diseases, such as osteoarthritis, are the key factors attributed to the high share. In 2022, the most lucrative product applications in the North America region were in the form of dermal fillers and viscos supplements for the management of osteoarthritis. Asia Pacific is anticipated to register the fastest CAGR during the forecast period.
The growing geriatric population in China and Japan provide a large customer base for anti-aging products and services. Rising awareness about product applications and efficacy also fuels the demand. In addition, increasing disposable income levels are further supporting the region's expansion. Europe has undergone impressive changes over the last 2 years. The growing demand is witnessing increasing price competition owing to new entrants. The WHO recently announced the obesity epidemic in the U.K. and Germany. The relationship between the increasing aging population and obesity is a potential driver for the Europe regional sector
Hyaluronic Acid Market Report Highlights:
- The osteoarthritis segment dominated the global industry and accounted for the maximum share of the overall revenue in 2023
- The rising obesity resulting in osteoarthritis and joint pain has increased the demand for hyaluronic acid injections as a treatment
- Hyaluronic acid acts as a shock absorber or a cushion and lubricates the joints, thus helping in proper functioning
- There are a number of ophthalmic surgical products that use hyaluronan/hyaluronic acid as an active ingredient
- These include Vitrax, Healon, Amivisc Plus, Amvisc, Hylan G-F20, and Opegan
- The increasing prevalence of age-related eye diseases, dry eye syndrome, adult-vision impairments, and chronic diseases, such as diabetes, are major factors leading to segment growth.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Application
- 1.2.2. Regional scope
- 1.2.3. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Application
- 2.2.2. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Hyaluronic Acid Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Increasing Geriatric Population
- 3.2.1.2. Growing Awareness for Antiaging Products
- 3.2.1.3. High Prevalence of Target Diseases
- 3.2.2. Market restraint analysis
- 3.2.2.1. Associated adverse effects of hyaluronic acid
- 3.2.2.2. High cost of products and related services
- 3.3. Hyaluronic Acid Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
Chapter 4. Hyaluronic Acid Market: Application Estimates & Trend Analysis
- 4.1. Application Market Share, 2023 & 2030
- 4.2. Segment Dashboard
- 4.3. Global Hyaluronic Acid Market by Application Outlook
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 - 2030 for the following
- 4.4.1. Dermal fillers
- 4.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 4.4.2. Osteoarthritis
- 4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 4.4.2.2. Single-injection
- 4.4.2.2.1 Market estimates and forecasts 2018 - 2030 (USD Million)
- 4.4.2.3. Three-injection
- 4.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 4.4.2.3. Five-injection
- 4.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 4.4.3. Ophthalmic
- 4.4.3.3. Market estimates and forecasts 2018 - 2030 (USD Million)
- 4.4.4. Vesicoureteral reflux
- 4.4.2.3. Market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 5. Hyaluronic Acid Market: Regional Estimates & Trend Analysis
- 5.1. Regional Market Share Analysis, 2023 & 2030
- 5.2. Regional Market Dashboard
- 5.3. Global Regional Market Snapshot
- 5.4. Market Size, & Forecasts Trend Analysis, 2018 - 2030:
- 5.5. North America
- 5.5.1. U.S.
- 5.5.1.1. Key country dynamics
- 5.5.1.2. Regulatory framework/ reimbursement structure
- 5.5.1.3. Competitive scenario
- 5.5.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
- 5.5.2. Canada
- 5.5.2.1. Key country dynamics
- 5.5.2.2. Regulatory framework/ reimbursement structure
- 5.5.2.3. Competitive scenario
- 5.5.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
- 5.6. Europe
- 5.6.1. UK
- 5.6.1.1. Key country dynamics
- 5.6.1.2. Regulatory framework/ reimbursement structure
- 5.6.1.3. Competitive scenario
- 5.6.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
- 5.6.2. Germany
- 5.6.2.1. Key country dynamics
- 5.6.2.2. Regulatory framework/ reimbursement structure
- 5.6.2.3. Competitive scenario
- 5.6.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
- 5.6.3. France
- 5.6.3.1. Key country dynamics
- 5.6.3.2. Regulatory framework/ reimbursement structure
- 5.6.3.3. Competitive scenario
- 5.6.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
- 5.6.4. Italy
- 5.6.4.1. Key country dynamics
- 5.6.4.2. Regulatory framework/ reimbursement structure
- 5.6.4.3. Competitive scenario
- 5.6.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
- 5.6.5. Spain
- 5.6.5.1. Key country dynamics
- 5.6.5.2. Regulatory framework/ reimbursement structure
- 5.6.5.3. Competitive scenario
- 5.6.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
- 5.6.6. Norway
- 5.6.6.1. Key country dynamics
- 5.6.6.2. Regulatory framework/ reimbursement structure
- 5.6.6.3. Competitive scenario
- 5.6.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
- 5.6.7. Sweden
- 5.6.7.1. Key country dynamics
- 5.6.7.2. Regulatory framework/ reimbursement structure
- 5.6.7.3. Competitive scenario
- 5.6.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
- 5.6.8. Denmark
- 5.6.8.1. Key country dynamics
- 5.6.8.2. Regulatory framework/ reimbursement structure
- 5.6.8.3. Competitive scenario
- 5.6.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
- 5.7. Asia Pacific
- 5.7.1. Japan
- 5.7.1.1. Key country dynamics
- 5.7.1.2. Regulatory framework/ reimbursement structure
- 5.7.1.3. Competitive scenario
- 5.7.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
- 5.7.2. China
- 5.7.2.1. Key country dynamics
- 5.7.2.2. Regulatory framework/ reimbursement structure
- 5.7.2.3. Competitive scenario
- 5.7.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
- 5.7.3. India
- 5.7.3.1. Key country dynamics
- 5.7.3.2. Regulatory framework/ reimbursement structure
- 5.7.3.3. Competitive scenario
- 5.7.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
- 5.7.4. Australia
- 5.7.4.1. Key country dynamics
- 5.7.4.2. Regulatory framework/ reimbursement structure
- 5.7.4.3. Competitive scenario
- 5.7.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
- 5.7.5. South Korea
- 5.7.5.1. Key country dynamics
- 5.7.5.2. Regulatory framework/ reimbursement structure
- 5.7.5.3. Competitive scenario
- 5.7.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
- 5.7.6. Thailand
- 5.7.6.1. Key country dynamics
- 5.7.6.2. Regulatory framework/ reimbursement structure
- 5.7.6.3. Competitive scenario
- 5.7.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
- 5.8. Latin America
- 5.8.1. Brazil
- 5.8.1.1. Key country dynamics
- 5.8.1.2. Regulatory framework/ reimbursement structure
- 5.8.1.3. Competitive scenario
- 5.8.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
- 5.8.2. Mexico
- 5.8.2.1. Key country dynamics
- 5.8.2.2. Regulatory framework/ reimbursement structure
- 5.8.2.3. Competitive scenario
- 5.8.2.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
- 5.8.3. Argentina
- 5.8.3.1. Key country dynamics
- 5.8.3.2. Regulatory framework/ reimbursement structure
- 5.8.3.3. Competitive scenario
- 5.8.3.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
- 5.9. MEA
- 5.9.1. South Africa
- 5.9.1.1. Key country dynamics
- 5.9.1.2. Regulatory framework/ reimbursement structure
- 5.9.1.3. Competitive scenario
- 5.9.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
- 5.9.2. Saudi Arabia
- 5.9.2.1. Key country dynamics
- 5.9.2.2. Regulatory framework/ reimbursement structure
- 5.9.2.3. Competitive scenario
- 5.9.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
- 5.9.3. UAE
- 5.9.3.1. Key country dynamics
- 5.9.3.2. Regulatory framework/ reimbursement structure
- 5.9.3.3. Competitive scenario
- 5.9.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
- 5.9.4. Kuwait
- 5.9.4.1. Key country dynamics
- 5.9.4.2. Regulatory framework/ reimbursement structure
- 5.9.4.3. Competitive scenario
- 5.9.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 6. Competitive Landscape
- 6.1. Recent Developments & Impact Analysis, By Key Market Participants
- 6.2. Company/Competition Categorization
- 6.3. Vendor Landscape
- 6.3.1. List of key distributors and channel partners
- 6.3.2. Key customers
- 6.3.3. Key company market share analysis, 2023
- 6.3.4. Allergan
- 6.3.4.1. Company overview
- 6.3.4.2. Financial performance
- 6.3.4.3. Product benchmarking
- 6.3.4.4. Strategic initiatives
- 6.3.5. Sanofi
- 6.3.5.1. Company overview
- 6.3.5.2. Financial performance
- 6.3.5.3. Product benchmarking
- 6.3.5.4. Strategic initiatives
- 6.3.6. Genzyme Corporation
- 6.3.6.1. Company overview
- 6.3.6.2. Financial performance
- 6.3.6.3. Product benchmarking
- 6.3.6.4. Strategic initiatives
- 6.3.7. Anika Therapeutics, Inc.
- 6.3.7.1. Company overview
- 6.3.7.2. Financial performance
- 6.3.7.3. Product benchmarking
- 6.3.7.4. Strategic initiatives
- 6.3.8. Salix Pharmaceuticals
- 6.3.8.1. Company overview
- 6.3.8.2. Financial performance
- 6.3.8.3. Product benchmarking
- 6.3.8.4. Strategic initiatives
- 6.3.9. Seikagaku Corporation
- 6.3.9.1. Company overview
- 6.3.9.2. Financial performance
- 6.3.9.3. Product benchmarking
- 6.3.9.4. Strategic initiatives
- 6.3.10. F. Hoffmann-La Roche Ag
- 6.3.10.1. Company overview
- 6.3.10.2. Financial performance
- 6.3.10.3. Product benchmarking
- 6.3.10.4. Strategic initiatives
- 6.3.11. Galderma Laboratories L.P.
- 6.3.11.1. Company overview
- 6.3.11.2. Financial performance
- 6.3.11.3. Product benchmarking
- 6.3.11.4. Strategic initiatives
- 6.3.12. Zimmer Biomet
- 6.3.12.1. Company overview
- 6.3.12.2. Financial performance
- 6.3.12.3. Product benchmarking
- 6.3.12.4. Strategic initiatives
- 6.3.13. Smith & Nephew Plc
- 6.3.13.1. Company overview
- 6.3.13.2. Financial performance
- 6.3.13.3. Product benchmarking
- 6.3.13.4. Strategic initiatives
- 6.3.14. Ferring B.V.
- 6.3.14.1. Company overview
- 6.3.14.2. Financial performance
- 6.3.14.3. Product benchmarking
- 6.3.14.4. Strategic initiatives
- 6.3.15. Lifecore Biomedical, LLC
- 6.3.15.1. Company overview
- 6.3.15.2. Financial performance
- 6.3.15.3. Product benchmarking
- 6.3.15.4. Strategic initiatives
- 6.3.16. HTL Biotechnology
- 6.3.16.1. Company overview
- 6.3.16.2. Financial performance
- 6.3.16.3. Product benchmarking
- 6.3.16.4. Strategic initiatives
- 6.3.17. Shiseido Company, Limited
- 6.3.17.1. Company overview
- 6.3.17.2. Financial performance
- 6.3.17.3. Product benchmarking
- 6.3.17.4. Strategic initiatives
- 6.3.18. Bloomage Biotechnology Corporation Limited
- 6.3.18.1. Company overview
- 6.3.18.2. Financial performance
- 6.3.18.3. Product benchmarking
- 6.3.18.4. Strategic initiatives
- 6.3.19. LG Life Sciences Ltd (LG Chem.)
- 6.3.19.1. Company overview
- 6.3.19.2. Financial performance
- 6.3.19.3. Product benchmarking
- 6.3.19.4. Strategic initiatives
- 6.3.20. Maruha Nichiro, Inc.
- 6.3.20.1. Company overview
- 6.3.20.2. Financial performance
- 6.3.20.3. Product benchmarking
- 6.3.20.4. Strategic initiatives